Kura Oncology Inc (KURA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $713.90M
Last updated: Nov 17, 2026 at 11:05 AM ET
Kura Oncology Inc (KURA) Competitors
The companies most similar to Kura Oncology are Oric Pharmaceuticals (ORIC), Olema Pharmaceuticals (OLMA) and Corvus Pharmaceuticals (CRVS). By market cap, Kura Oncology ranks 5th of the 13 companies on this page; Nurix Therapeutics (NRIX) is the largest at $1.69B.
Peer Comparison
KURA's ROIC of -1125.3% is below the peer median of -25.7%, and its revenue growth of 10.1% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Kura Oncology (KURA) | $713.90M | N/A | 8.0x | 0.0% | -1125.3% | 10.1% | 0.00% |
| Oric Pharmaceuticals Inc (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Corvus Pharmaceuticals Inc (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cullinan Oncology LLC (CGEM) | $667.39M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | $683.26M | N/A | 8.1x | -124.8% | -7.3% | 178.1% | 0.00% |
| Candel Therapeutics Inc (CADL) | $486.37M | N/A | N/A | 0.0% | -43.5% | 0.0% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Surrozen Inc (SRZN) | $602.54M | N/A | 36.1x | 0.0% | N/A | 408.6% | 0.00% |
| Peer median | $675.32M | 6.4x | 8.1x | 0.0% | -25.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Kura Oncology, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Oric Pharmaceuticals Inc (ORIC) | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. | ORIC competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
| Corvus Pharmaceuticals Inc (CRVS) | Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. | CRVS competitors |
| Cullinan Oncology LLC (CGEM) | Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients... | CGEM competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. | |
| Candel Therapeutics Inc (CADL) | Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform... | CADL competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Surrozen Inc (SRZN) | Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform... | SRZN competitors |
Frequently Asked Questions About KURA
Who are Kura Oncology's main competitors?
The companies most similar to Kura Oncology include Oric Pharmaceuticals (ORIC), Olema Pharmaceuticals (OLMA), Corvus Pharmaceuticals (CRVS), Cullinan Oncology LLC (CGEM) and CytomX Therapeutics (CTMX), listed from the closest match.
Who is Kura Oncology's biggest competitor?
Nurix Therapeutics (NRIX) is the largest of the similar companies at $1.69B; Oric Pharmaceuticals (ORIC) is the closest match by business profile, size, sector and industry.
How does KURA stock compare with its competitors?
KURA's P/S is 8.0x against a peer median of 8.1x; its net margin is 0.0% against a peer median of 0.0%.
Which of Kura Oncology's competitors pays a higher dividend?
Kura Oncology pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Kura Oncology bigger than its competitors?
No. Kura Oncology is 5th by market cap among the 13 companies on this page; the largest is Nurix Therapeutics (NRIX) at $1.69B.
KURA pages: Overview, Earnings, Forecast, Financials, Competitors